SCHEMBL4417268

SCHEMBL4417268

Cc1nccn1CCC(=O)N1CCN(c2ccc(Cl)cc2)CC1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 2/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HTR1A P08908 2/20 0.41
▸ LMNA P02545 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MC4R P32245 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ NR1H2 P55055 2/20 0.38
▸ NR1H3 Q13133 2/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ F10 P00742 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417933 0.90 ESR1 (0.47) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4428545 0.83 ALDH1A1 (0.40) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4425311 0.82 HTR7 (0.43) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4430303 0.78 HTR7 (0.42) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4417265 0.75 MEN1 (0.43) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4423590 0.74 ESR1 (0.42) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL4422476 0.73 HTR7 (0.60) HTR7MEN1KMT2AMAPTHTR1A
SCHEMBL683003 0.72 PDE4B (0.42) NR1H2NR1H3
SCHEMBL876880 0.72 PDE4B (0.42) NR1H2NR1H3
SCHEMBL2116079 0.71 MEN1 (0.49) HTR7MEN1KMT2AMAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-12-31 — — US claimed
US-8492384-B2 Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 — — US disclosed
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1B, CACNA1C, ORAI1 HTR7 816/4885MEN1 2657/4885KMT2A 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback